[Clinical studies on 6059-S in the field of pediatrics (author's transl)].
6059-S was administered to 32 children with various acute bacterial infections (bronchopneumonia 11, bronchitis 1, pyelonephritis 5, acute enteritis 6, purulent infection 4, secondary infection due to agranulocytosis 5) at the dose of 21 to 190 mg/kg/day for 2 to 12 days. The clinical response of 6059-S was very satisfactory in all 17 cases with the injection of respiratory tract or urinary tract infection, but it was not so favourable in 5 cases of secondary infection due to agranulocytosis. The overall clinical response was excellent in 5, good in 20, fair in 4, and failure in 3 with effective rate of 78%. As to side effect, each one case diarrhea and elevation of GOT and GPT was noted.
D000208:Acute Disease; D000293:Adolescent; D000367:Age Factors; D000380:Agranulocytosis / Q000150:complications; D001424:Bacterial Infections / Q000188:drug therapy*; D002511:Cephalosporins / Q000008:administration & dosage*; D002513:Cephamycins / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D004751:Enteritis / Q000188:drug therapy; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009070:Moxalactam; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D013492:Suppuration / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
D002511:Cephalosporins; D002513:Cephamycins; D009070:Moxalactam